Connect Biopharma Holdings (CNTB) Return on Capital Employed (2025 - 2026)
Connect Biopharma Holdings (CNTB) posted quarterly Return on Capital Employed of 161.45% for Q1 2026, down 13739.0% year-on-year from N/an in Q1 2025, and down 33.73% on a QoQ basis from 120.72% in Q4 2025.
Connect Biopharma Holdings (CNTB) Return on Capital Employed (2025 - 2026) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Return on Capital Employed for 2 consecutive years, with 161.45% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 13739.0% year-over-year to 161.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.45% (down 13739.0% YoY) and the FY2025 annual result came in at 89.25%, down 6805.0% from the prior year.
- Return on Capital Employed eased to 161.45% in Q1 2026 per CNTB's latest filing, from 120.72% in the prior quarter.
- Over the last five years, Return on Capital Employed for CNTB reached as high as 24.05% in Q1 2025 and fell as low as 161.45% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Connect Biopharma Holdings | 120.44 Mn | 120.44 Mn | - | -161.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -161.45% |
| Dec 31, 2025 | -120.72% |
| Sep 30, 2025 | -82.00% |
| Jun 30, 2025 | -62.80% |
| Mar 31, 2025 | -24.05% |